R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

1 year ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID drugs sent to developing countries; and J&J is set to begin human testing of its own COVID-19 drug.

GSK’S MULTIPLE MYELOMA DRUG FDA-APPROVED DESPITE SAFETY FEARS – Despite FDA concerns around danger to patients’ eyes, GSK’s first-in-class multiple myeloma drug belantamab mafodotin has been backed by a panel of FDA expert advisers. The drug is expected to The regulatory is expected to come to a final decision in the next few weeks. 

ROCHE AND BLUEPRINT SIGN $1.7 BILLION DEAL ON CANCER DRUG – Roche and cancer drug company Blueprint have signed a deal worth up to $1.7 billion over pralsetinib, a drug targeting tumours with RET mutations. The two companies will equally market the drug and share profits and losses in the U.S. This deal will see Roche come into competition with Eli Lilly, whose RET inhibitor is already approved by the FDA. 

NOVARTIS PROMISES TO MAKE NO PROFIT FROM 15 COVID DRUGS IN POOR COUNTRIES – Novartis’s Sandoz unit has promised to offer 15 generic and over-the-counter medicines for no profit to developing countries while the COVID-19 pandemic continues. The range of drugs will cover cardiovascular and gastrointestinal diseases, and in particular dexamethasone, which has shown to cut death rates in severely ill coronavirus patients. 

In other news:

Clinical Trials
Bayer/Merck’s heart failure drug vericiguat receives FDA fast review
J&J to begin human testing of COVID-19 drug

Manufacturing
Moderna begins production of COVID vaccine for at-risk patients
FDA reveals plans for restarting domestic inspections

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

RNA Therapeutics: Innovations in Disease Research and Drug Development

RNA has proven in the last decade to be a valid therapeutic target for a multitude of diseases. The ability to manipulate the genetic code to produce almost any protein is one of the many advantages that has also led...

3 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

RNA Therapeutics: Innovations in Disease Research and Drug Development

RNA has proven in the last decade to be a valid therapeutic target for a multitude of diseases. The ability to manipulate the genetic code to produce almost any protein is one of the many advantages that has also led...

3 weeks ago

Emerging Innovations in Translational Medicine: An Interview with Marcie Glicksman, Enclear Therapies

3D cultures and organ-on-a-chip are a few examples of technologies that hope to bridge the gap from benchside to clinic. Failures that arise during drug development often arise due to poor translatability from models in preclinical studies to the patients...

3 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Emerging Innovations in Translational Medicine: An Interview with Marcie Glicksman, Enclear Therapies

3D cultures and organ-on-a-chip are a few examples of technologies that hope to bridge the gap from benchside to clinic. Failures that arise during drug development often arise due to poor translatability from models in preclinical studies to the patients...

3 weeks ago

Drugs in Space: How Extraterrestrial Experiments Help Us Develop Medicine

Over the last 20 years, fundamental scientific research has been conducted by astronauts aboard the international space station (ISS). It has only been recently that the pharmaceutical and biotech sectors have invested in extraterrestrial experiments, hoping to find novel ways...

3 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Drugs in Space: How Extraterrestrial Experiments Help Us Develop Medicine

Over the last 20 years, fundamental scientific research has been conducted by astronauts aboard the international space station (ISS). It has only been recently that the pharmaceutical and biotech sectors have invested in extraterrestrial experiments, hoping to find novel ways...

3 weeks ago
Working With us

Interested?
Reserve your space